Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
August 07 2024 - 9:15AM
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;
"Cyclacel" or the "Company"), a biopharmaceutical company
developing innovative medicines based on cancer cell biology, will
announce second quarter 2024 financial results on Wednesday, August
14, 2024. The Company will host a conference call and live webcast
at 4:30 p.m. Eastern Daylight Time on the same day.
Conference call
information:
Call: (800) 225-9448 / international call: (203)
518-9708
Archive: (800) 934-7884 / international archive:
(402) 220-6987
Code for live and archived conference call is
CYCCQ224. Webcast link
For the live and archived webcast, please visit the
Corporate Presentations page on the Cyclacel website
at www.cyclacel.com. The webcast will be archived for 90 days
and the audio replay for 7 days.
About Cyclacel Pharmaceuticals,
Inc.
Cyclacel is a clinical-stage,
biopharmaceutical company developing innovative cancer medicines
based on cell cycle, transcriptional regulation and mitosis
biology. The transcriptional regulation program is evaluating
fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program
plogosertib, a PLK1 inhibitor, in patients with both solid tumors
and hematological malignancies. Cyclacel's strategy is to
build a diversified biopharmaceutical business based on a pipeline
of novel drug candidates addressing oncology and hematology
indications. For additional information, please
visit www.cyclacel.com.
Forward-looking Statements
This news release contains certain
forward-looking statements that involve risks and uncertainties
that could cause actual results to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. Such forward-looking statements
include, among other things, statements related to the intended use
of proceeds from the private placement. Factors that may cause
actual results to differ materially include market and other
conditions, the risk that product candidates that appeared
promising in early research and clinical trials do not demonstrate
safety and/or efficacy in larger-scale or later clinical trials,
trials may have difficulty enrolling, Cyclacel may not
obtain approval to market its product candidates, the risks
associated with reliance on outside financing to meet capital
requirements, the risks associated with reliance on collaborative
partners for further clinical trials, development and
commercialization of product candidates and Cyclacel's ability to
regain and maintain compliance with Nasdaq's continued listing
requirements. You are urged to consider statements that include the
words "may," "will," "would," "could," "should," "believes,"
"estimates," "projects," "potential," "expects," "plans,"
"anticipates," "intends," "continues," "forecast," "designed,"
"goal," or the negative of those words or other comparable words to
be uncertain and forward-looking. For a further list and
description of the risks and uncertainties the Company faces,
please refer to our most recent Annual Report on Form 10-K and
other periodic and other filings we file with the Securities
and Exchange Commission and are available at www.sec.gov.
Such forward-looking statements are current only as of the date
they are made, and we assume no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts
Company: |
Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com |
Investor Relations: |
Grace Kim, IR@cyclacel.com |
|
|
© Copyright 2024 Cyclacel Pharmaceuticals, Inc. All
Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCCP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCCP)
Historical Stock Chart
From Aug 2023 to Aug 2024